Expanded Access Program (EAP): how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What EAP is

Origin and authorising body. United States Food and Drug Administration under 21 CFR 312 Subpart I; parallel programmes exist in most major regulators (EMA, MHRA, Health Canada, TGA). The authorising body for each individual case is the United States Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER), with parallel destination-country regulator review for cross-border supply, acting under that jurisdiction's pharmacy or medicines legislation.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Legal basis. 21 CFR 312 Subpart I authorises the FDA to permit the use of an investigational new drug for the diagnosis, monitoring, or treatment of a serious disease or condition in a patient who lacks comparable or satisfactory therapeutic alternatives and for whom the potential benefit of the drug justifies the potential risk. Subpart I distinguishes three categories: individual patient expanded access (21 CFR 312.310), intermediate-size patient populations (21 CFR 312.315), and treatment IND or treatment protocol for widespread use (21 CFR 312.320).

Expanded Access Program is the United States FDA framework for providing investigational medicines to patients outside clinical trials. It is the original architectural template that most other compassionate-use programmes worldwide have borrowed from. The framework distinguishes between three tiers: individual patient IND (for a single named patient), intermediate-size patient population (for a defined group with a common condition where formal trial enrolment is not feasible), and treatment IND or treatment protocol (for widespread use of a promising investigational drug late in development). Each tier has its own documentation depth and regulator review timeline.

An individual patient IND can be submitted under emergency conditions by phone or fax to the FDA, with written follow-up within 15 working days, when the treating physician concludes that the patient's condition requires immediate access. Non-emergency individual patient INDs are submitted in writing and the FDA has 30 days to object before treatment may begin. Intermediate-size and treatment INDs require a written protocol, informed consent documentation, IRB review, and a detailed monitoring plan. The sponsor (typically the manufacturer, but in single-patient cases the treating physician can act as sponsor-investigator) carries the formal IND. For cross-border supply into a Gulf or other destination country, the FDA Expanded Access authorisation pairs with a destination-country named-patient or compassionate-use permit; both clearances must be in place before shipment.

This page consolidates Reserve Meds's operational view of the Expanded Access Program framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Expanded Access Program-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use EAP

Expanded Access is used by US physicians on behalf of patients with serious or life-threatening conditions for whom no comparable or satisfactory therapy is available and who cannot enrol in an ongoing clinical trial. Internationally, treating physicians outside the US can route US-manufactured investigational medicines to their patients through a combination of FDA Expanded Access (on the US side, authorising supply) and the destination country's named-patient or compassionate-use pathway (on the receiving side, authorising import). The receiving physician is the clinical decision-maker; the FDA Expanded Access IND establishes that the manufacturer can legally ship the investigational product.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under EAP

Investigational oncology agents (CAR-T constructs, novel checkpoint inhibitors, ADCs in development), investigational rare-disease therapies (gene therapies, enzyme replacement therapies in late-phase development), investigational antivirals and antibacterials for resistant pathogens, post-approval extensions where the FDA-approved indication does not match the patient's clinical presentation, and paediatric formulations not yet through full registration.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Expanded Access Program import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Expanded Access Program framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Expanded Access Program dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Expanded Access Program clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Expanded Access Program authorisation as the legal basis for import but does recognise a Expanded Access Program authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A EAP application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Physician-initiated Form FDA 3926 (individual patient expanded access) or full IND submission (intermediate-size or treatment protocol).
• Treating physician's clinical summary including diagnosis, disease history, prior treatments, current clinical status, and rationale for the requested medicine.
• Informed consent document specific to expanded access.
• IRB or equivalent ethics review (concurrent IRB review acceptable for emergency individual patient cases).
• Manufacturer letter of authorisation to cross-reference the existing IND, or a fully assembled IND if the physician is acting as sponsor-investigator.
• Treatment plan including dosing, monitoring, and adverse event reporting.
• For cross-border cases: parallel destination-country named-patient or compassionate-use application.

Typical timeline

Emergency individual patient expanded access can be authorised by phone within 24 hours, with the written submission following within 15 working days. Non-emergency individual patient applications have a 30-day FDA review clock during which treatment cannot begin unless the FDA affirmatively authorises earlier start. Intermediate-size and treatment INDs run on full IND review timelines (30 days minimum for FDA review, plus IRB review in parallel). For cross-border patients, the FDA Expanded Access step is one of two regulatory clearances required (the destination country's named-patient permit being the other), and end-to-end timelines commonly run 4 to 8 weeks for routine cases.

Costs and reimbursement

21 CFR 312.8 permits cost recovery for an investigational drug under expanded access; the manufacturer may charge for direct costs of making the drug available (manufacturing, shipping, monitoring, administrative). Cost recovery is not automatic and the manufacturer must justify the recovery price to the FDA. Some manufacturers provide expanded-access medicines free of charge as a managed-access programme cost; others charge. Insurer reimbursement for expanded-access drugs is uncommon, and patients commonly pay the manufacturer's cost-recovery price plus international logistics, customs, dispensing handling, and coordinator fees. Manufacturer copay cards do not extend to expanded-access supply.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Expanded Access Program cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Expanded Access Program framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works